Overview
International law firm McDermott Will & Emery represented REGENXBIO in its $1.8 billion strategic partnership with AbbVie to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases.
The McDermott team was led by Krist Werling and included Rich Smith, Monika Richter, Andrea Hamilton and Becky DuFur. Tom Conaghan is the relationship partner for REGENXBIO.
Read REGENXBIO’s press release here.
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
